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Summary 
 
Background and Purpose 
The β1-adrenoceptor has at least two binding sites, high and low affinity sites1H and 1L, 
respectively), which mediate cardiostimulation. While β1H- adrenoceptor can be blocked by 
all clinically used β-blockers, β1L-adrenoceptor is relatively resistant to blockade. Thus, 
chronic β1L-adrenoceptor activation may mediate persistent cardiostimulation, despite the 
concurrent blockade of β1H-adrenoceptors. It is important to determine the potential 
significance of β1L-adrenoceptors in vivo, particularly in the setting of disease. 
 
Experimental Approach 
C57Bl/6 male mice were used. Chronic (4 or 8 weeks) β1L-adrenoceptor activation was 
achieved by treatment, via osmotic minipumps, with (-)-CGP12177 (10 mg kg-1 day-1). 
Cardiac function was assessed by echocardiography and micromanometry.  
 
Key Results 
(-)-CGP12177 treatment in healthy mice increased heart rate and left ventricular (LV) 
contractility. In mice subjected to transverse aorta constriction (TAC), (-)-CGP12177 
treatment during 4-8 or 4-12 weeks, respectively, after TAC led to a positive inotropic effect 
and exacerbated fibrogenic signalling while cardiac hypertrophy tended to be more severe. 
(-)-CGP12177 treatment to mice with TAC exacerbated myocardial expression of 
hypertrophic, fibrogenic and inflammatory genes (all P<0.05 vs. non-treated mice with aorta 
banding). Washout of (-)-CGP12177 revealed a more pronounced cardiac dysfunction after 
12 weeks TAC. 
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Conclusions and Implications 
β1L-adrenoceptor activation provides functional support to the heart, in both normal and 
diseased (pressure overload) settings. Sustained β1L-adrenoceptor activation in the diseased 
heart exacerbates LV remodelling and therefore may promote disease progression from 
compensatory hypertrophy to heart failure. 
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1L or 1H: low or high affinity binding site of 1-adrenoceptor; LV: left ventricle or left 
ventricular; TAC: transverse aorta constriction; HF: heart failure, HR: heart rate; FS: 
fractional shortening. 
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Introduction 
The 1-adrenoceptor is activated by (-)-noradrenaline (Alexander et al., 2011) and 
blocked by all clinically used -blockers. Some -blockers, typified by (-)-CGP12177 and 
(-)-pindolol, not only block the 1-adrenoceptor, but also activate it at higher concentrations 
(~100 fold) than those required to block it (Kaumann and Molenaar, 2008). To accommodate 
these findings, it was hypothesised that -blockers such as (-)-CGP12177 and (-)-pindolol 
bind to the 1-adrenoceptor at two different sites, one that blocks (-)-noradrenaline from 
activating the receptor, the 1H site, and another that activates the receptor, the 1L site. The 
concept of two separate binding sites on the 1-adrenoceptor has been strongly supported by 
findings from experiments carried out on cell lines containing recombinant 1-adrenoceptors 
(Baker, 2005; Baker et al., 2003; Joseph et al., 2004; Joseph et al., 2003; Kaumann and 
Molenaar, 2008; Konkar et al., 2000a; Konkar et al., 2000b; Pak and Fishman, 1996), cells 
and tissues including those from 1-adrenoceptor knockout mice (Kaumann et al., 2001; 
Konkar et al., 2000a) and molecular modelling (Baker et al., 2008). 
The physiological effects of activation of 1L-adrenoceptors are observed in the heart ex 
vivo, from humans (Joseph et al., 2003; Kaumann, 1996; Sarsero et al., 2003) and other 
species (reviewed (Kaumann and Molenaar, 2008)) including mice (Kaumann et al., 2001; 
Kaumann et al., 1998) where (-)-pindolol and related indolamines, (-)-CGP12177 and other 
-blockers such as oxprenolol and (-)-alprenolol, cause cardiostimulant effects (Kaumann 
and Molenaar, 2008).   
Blockade of β1-adrenoceptors is a fundamental requirement of all β-blockers currently 
used for the management of heart failure (HF) (Bristow, 2000; Bristow et al., 2003; Molenaar 
and Parsonage, 2005). Clinically used β-blockers block or activate β1L-adrenoceptors only at 
much higher concentrations than those that block β1H-adrenoceptors (Kaumann and 
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Molenaar, 2008). Chronic activation of the sympatho–β-adrenergic system causes 
progression of HF and hastens mortality (Bristow, 2000; Cohn et al., 1984; Esler et al., 
1997). Long-term administration of β-blockers results in haemodynamic improvement and 
reduced morbidity and mortality (Colucci et al., 1996; MERIT, 1999; Packer et al., 1996; 
Packer et al., 2001; Waagstein et al., 1993; Waagstein et al., 1975). However, despite the use 
of β-blockers, HF remains progressive and the long-term prognosis after HF diagnosis is 
poor. 
The sympathomimetic effects of some β-blockers, mediated through β1L-adrenoceptors, 
could conceivably reduce the benefit of blockade of β1H-adrenoceptors, thereby reducing 
efficacy in the treatment of HF. Bucindolol is such a β-blocker (Bundkirchen et al., 2002), 
and was shown to lack efficacy in HF (BEST, 2001). Pindolol is known to aggravate 
arrhythmias in patients with ischaemic heart disease (Podrid and Lown, 1982). Furthermore, 
(-)-CGP12177 causes arrhythmic Ca2+ transients in murine ventricular myocytes (Freestone 
et al., 1999). Cardiostimulation by compounds with similar properties could conceivably be 
harmful in HF. This idea is based entirely on the known effects of chronic activation of β1H-
adrenoceptors in the context of human HF, and consistency of coupling with the Gsα-
protein/cyclic AMP-protein kinase A pathway for both β1H and β1L-adrenoceptors (Kaumann 
and Lynham, 1997; Kaumann and Molenaar, 2008; Sarsero et al., 2003). However, before 
this hypothesis can be properly formulated, it is necessary to determine whether activation of 
β1L-adrenoceptors causes progression of HF.  
We sought to address this question in vivo firstly to define the dose-effect relationship of 
acute and chronic treatment with (-)-CGP12177, and secondly to examine whether chronic 
β1L-adrenoceptor stimulation using (-)-CGP12177 in the setting of pressure overload by 
transverse aorta constriction (TAC) alters development of cardiac hypertrophy and 
dysfunction (Du et al., 2000; Gao et al., 2005; Kiriazis et al., 2008). Our results demonstrate 
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chronically stimulatory effects by β1L-adrenoceptor activation on cardiac function and that 
sustained β1L-adrenoceptor activation in the heart exacerbates left ventricular (LV) 
remodelling and dysfunction.  
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Methods 
Animals. All animal procedures were approved by a local Animal Ethics Committee and 
in accordance to guidelines set out in the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes (7th Ed). We consulted the ARRIVE and British Journal of 
Pharmacology guidelines for in vivo animal studies (Kilkenny et al., 2010; McGrath et al., 
2010). C57Bl/6 male mice aged 10-12 weeks were used. A strain of mice with β3-
adrenoceptor knockout (β3ARKO) and of FVB/n genetic background were used at 10-12 
weeks of age. Animals were housed at two to four per cage, had free access to food and 
water, and were maintained on a 12:12 h light-dark cycle. Analgesia (carprofen, 5 mg kg-1) 
was administered at surgery. 
Echocardiography. Serial echocardiographic tests were performed in anaesthetised mice, 
using ketamine/xylazine/atropine (80/10/1.2 mg kg-1, ip) or isoflurane (~2%), and a Philips 
iE33 echocardiography system with a L15-7io compact linear-array transducer. As described 
previously (Kiriazis et al., 2008), after obtaining 2-dimensional LV short-axis images, M-
mode traces were acquired for measurement of LV wall thickness, LV chamber dimensions at 
diastole and systole, echocardiography-derived LV mass, fractional shortening (FS) and heart 
rate (HR). 
Micromanometry. The acute dose-effect relation of (-)-CGP12177 on haemodynamic 
measures was examined. Mice were anaesthetised with ketamine/xylazine/atropine (80/10/1.2 
mg kg-1, ip), and a 1.4 Fr Millar Mikro-tip catheter was positioned in the ascending aorta via 
the right carotid artery, and then advanced into the LV, as previously described (Du et al., 
2000; Gao et al., 2005). (-)-CGP12177 was infused intravenously as a bolus (0.1 ml per 
mouse) from 0.001 to 10 mg kg-1. As the recovery from the effects of (-)-CGP12177 is very 
slow (Zakrzeska et al., 2005), each dose of the drug was administered in separate animals. 
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Haemodynamics was also examined at the end of Experiment-1 and -2 (see below). Mice 
were anaesthetised with isoflurane (4% for induction and 1.7% for maintenance). Steady state 
of aortic systolic and diastolic pressures (SAP, DAP), pulse pressure, HR, LV systolic and 
end-diastolic pressures (LVSP, LVEDP) were measured. Indices of LV contractility and 
relaxation (dP/dtmax and dP/dtmin, respectively), contractility index (dP/dtmax/instantaneous 
pressure) and tau (relaxation index) were calculated using Chart5 software (ADInstruments).  
 (-)-CGP12177 and osmotic minipump implantation. (-)-CGP12177 was custom made 
by Sigma-Aldrich at a purity of 98.2% (FW=315.8). To test the in vivo chronic effects of (-)-
CGP12177, mice anaesthetised with ketamine/xylazine/atropine (100/20/1.2 mg kg-1, ip) 
were implanted with an Alzet osmotic minipump (model 2004, DURECT Corporation) 
containing (-)-CGP12177, dissolved in purified H2O to the required concentration.  
Transverse aorta constriction (TAC) surgery and animal monitoring. The details of 
surgery were described previously (Du et al., 2000; Gao et al., 2005). In brief, animals were 
anaesthetised with a mixture of ketamine/xylazine/atropine (100/20/1.2 mg kg-1, i.p.). 
Animals were intubated and ventilated. A midline incision was made at the upper sternum 
and the aorta was dissected between the right innominate and the left carotid arteries. The 
aorta was then constricted by approximately 70% to a lumen size of 0.4 mm. Sham operated 
mice were subjected to the same surgery except for the banding of the aorta. The mortality 
during surgery and within the first 24 hours after the surgery was about 5%. Each animal was 
under close monitoring post surgery. If an animal was found to be unwell, routine treatment 
was applied following a Standard Operation Procedure, implemented by our local animal 
ethics committee, which included procedures such as keeping the animal warm and providing 
easy access to food and water. If the animal did not respond to treatment by 48 hours, or 
showed signs of deterioration, it was killed humanely and counted as “premature death”. 
Presence of HF was determined by subsequent autopsy findings. 
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Autopsy and histology. Following micromanometry, the chest cavity was inspected for 
evidence of pleural effusion, a blood sample was collected via cardiac puncture, and atria, 
ventricles, and lungs were dissected, blotted and weighed. Body mass (excluding minipump) 
was recorded. LV was frozen for chemical assay and a mid LV cross-sectional ring was fixed 
in neutral buffered formaldehyde (pH=7), paraffin-embedded, cut into 5 m sections and 
stained with Masson’s trichrome or picrosirius red for analyses using ImagePro-6 software 
(Media Cybernetics, Inc.). Interstitial fibrosis was quantified in 8-10 representative views per 
LV section with results expressed as the percentage of the LV cross-sectional area. 
Cardiomyocyte diameter was determined from 10-12 randomly selected fields per LV section 
with the average from 70-100 cells used, as previously described (Gao et al., 2005). Analyses 
were performed in a blinded fashion.  
Gene expression. Total RNA was extracted from LV tissues and gene transcripts of atrial 
or brain natriuretic peptide, - or -myosin heavy chain, -skeletal actin, -smooth muscle 
actin, β1-adrenoceptor, sarcoplasmic reticulum Ca2+-ATPase, transforming growth factor-, 
connective tissue growth factor, procollagen I, procollagen III, matrix metalloproteinase 2, 
interleukin-1, interleukin-6, monocyte chemotactic protein-1, and NADPH oxidase 2 were 
determined, in duplicates, by quantitative real-time PCR as described previously (Gao et al., 
2005; Xu et al., 2011). Gene expression levels were normalised to glyceraldehyde-3-
phosphate dehydrogenase. The level of change was expressed as fold of sham-operated 
control. 
Plasma renin. Plasma was assayed in duplicates for renin activity via the ProSearch 
International Australia Pty Ltd using radioimmunoassay.  
Radioligand binding.  LV myocardium was frozen in liquid nitrogen and stored at -70°C 
until use. Ventricular myocardium was homogenised in ice-cold Tris/Mg2+ assay buffer (in 
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mM: Tris HCl 50, EGTA 5, EDTA 1, MgCl2 4, ascorbic acid 1, phenylmethylsulphonyl 
fluoride 0.5, and pH=7.4), centrifuged at 50,000 g and the pellet resuspended in assay buffer. 
A single point binding experiment at high-affinity β-adrenoceptor binding sites (the site 
through which (-)-CGP12177 antagonizes the effects of catecholamines) was carried out with 
2 nM (-)-[3H]CGP12177 (specific activity ~40 Ci mmole-1) with non-specific binding 
determined with 500 nM (-)-propranolol (Sarsero et al., 1998; Sarsero et al., 1999). Low-
affinity binding sites (the site through which (-)-CGP12177 elicits cardiostimulant effects) 
were determined with 20 nM (-)-[3H]CGP12177 in the presence of 500 nM (-)-propranolol 
with non-specific binding determined with 20 μM (-)-CGP12177 (Sarsero et al., 1998; 
Sarsero et al., 1999). Assays were carried out at 37°C for 120 min. The fraction of high and 
low affinity binding sites occupied was determined using the mass action equation and 
equilibrium dissociation constants of (-)-[3H]CGP12177 determined previously in mouse 
ventricle at high affinity (0.63 nM) and low affinity (105 nM) binding sites (Kaumann et al., 
2001). This was then used to determine the maximal density of binding sites, standardized 
against protein content. Protein was determined using the Bradford reagent (Sigma-Aldrich).  
 
Protocol of (-)-CGP12177 treatment in mice with TAC.  C57Bl/6 mice underwent TAC 
or sham surgery. Four weeks post-surgery, echocardiography was performed under 
ketamine/xylazine/atropine anaesthesia. To reduce risk of animal loss in the latter stages of 
TAC during cardiac functional assessment, isoflurane (4% induction, 1.7% maintenance) was 
used for the rest of functional examinations by echocardiography and micromanometry. Just 
prior to the week-4 echocardiography test, half of the TAC mice were randomly allocated to 
the (-)-CGP12177 treatment group (TAC+CGP). Immediately after echocardiography these 
TAC mice underwent surgery to implant minipumps containing (-)-CGP12177 (10 mg kg-1 
day-1), as described above. The other half of the TAC mice were allocated to the untreated 
group (TAC). Drug treatment lasted either for 4 weeks (Experiment-1) or 8 weeks 
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(Experiment-2), the latter requiring a 2nd minipump surgery to replace the initial minipump 
with a fresh one. Echocardiographic tests were conducted 4 weeks (i.e. week 8 after TAC, 
Experiment-1) or 8 weeks post minipump implantation (i.e. week 12 after TAC, Experiment-
2). In Experiment-1, micromanometry was conducted within 2 days after the last 
echocardiographic test but in the presence of (-)-CGP12177. In order to evaluate intrinsic 
cardiac function in the absence of (-)-CGP12177, in Experiment-2, minipumps were removed 
following the last (12 weeks) echocardiography. Echocardiography was then repeated 3 days 
later, and micromanometry was performed on the following day. Figure 1 depicts protocols 
adopted.  
Statistics.  Results are presented as mean±standard error, unless otherwise indicated. 
Statistical analyses were performed with SigmaStat v3.5 and GraphPad Prism 5 software, 
using analysis of variance followed by Student-Neuman-Keuls post hoc test, or using 
Student’s unpaired t test. Incidence was compared between groups by 2 test. Differences 
were considered statistically significant at P<0.05. 
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Results 
Cardiac effects of chronic infusion of (-)-CGP12177 in healthy mice.  We tested the 
dose-dependent cardiac effects of (-)-CGP12177 by infusion via osmotic minipumps at 6 
different doses (0.01, 0.1, 1, 10, 30 and 100 mg kg-1 day-1) for a period of 4 weeks. 
Echocardiographic tests were performed at 2 and 4 weeks after treatment commenced. 
Compared to vehicle control group, (-)-CGP12177 treated groups showed significant 
increases in HR and FS measured at 2 and 4 weeks (Figure 2A). Such effects were dose-
dependent within the range of 0.01 to 10 mg kg-1 day-1 with no further increase of the cardiac 
parameters measured at doses of 30 and 100 mg kg-1 day-1 versus that of 10 mg kg-1 day-1 
group. To assess whether chronic infusion with (-)-CGP12177 at 1100 mg kg-1 day-1 caused 
persistent alterations to cardiac function, osmotic minipumps were removed and 3 days later, 
echocardiography was repeated. HR and FS values returned towards control levels (Figure 
2A). Chronic infusion of (-)-CGP12177 had no effect on LV or whole heart mass (data not 
shown). Based on these results, a dose of 10 mg kg-1 day-1 was selected for further studies on 
mice with TAC. 
Anaesthesia is known to reduce sympathetic nervous activity, particularly with the 
ketamine/zylazine mixture (Tan et al., 2003), which might prevent demonstration of the 1H-
adrenoceptor blocking action of (-)-CGP12177. To demonstrate the effects of (-)-CGP12177 
at 1H-adrenoceptors, we tested the effects of (-)-CGP12177 on the HR of conscious mice that 
were stressed by being restrained (hand-held in a supine position for approximately 20 sec). 
HR was assessed using echocardiography. We have previously shown that this procedure is 
associated with significant sympathetic activation due to the stress associated with being 
restrained (Tan et al., 2003). Echocardiographic test was performed at “baseline” and 
repeated at 5, 30 and 70 min after intraperitoneal injection of (-)-CGP12177 at 0.001 mg kg-1. 
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After administration of (-)-CGP12177, HR was 17% below baseline at 5 min, and although 
slightly recovered, remained still lower at 70 min (Figure 3A), apparently due to blockade of 
1H-adrenoceptors by (-)-CGP12177. 
We further evaluated the acute dose-effect relation of (-)-CGP12177 on haemodynamic 
measures. (-)-CGP12177 induced a dose-dependent increase in HR and contractility 
measured as dP/dtmax, dP/dtmin and contractility index (Figure 3B). Contractile response 
reached plateau at i.v. approximately 0.1 mg kg-1 of (-)-CGP12177.  
Effect of (-)-CGP12177 on cardiac gene expression and β-adrenoceptor density.  
Expression of 17 genes was examined in the LV of mice without or with treatment of (-)-
CGP12177 at 10 mg kg-1 day-1 for 4 weeks. There were no significant differences between 
treated and untreated mice in any of the genes examined (data not shown). Chronic infusion 
of (-)-CGP12177 at 10 and 30 mg kg-1 day-1, but not 1 mg kg-1 day-1, for 4 weeks caused a 
reduction in (-)-[3H]-CGP12177 β1H-adrenoceptor and β2-adrenoceptor binding sites (Table 
1).   
Effect of (-)-CGP12177 on β3-adrenoceptors. Controversy exists about whether the 
cardiostimulant effects of (-)-CGP12177 in human atrium are caused by activation of β3-
adrenoceptors (Skeberdis et al., 2008) or β1L-adrenoceptors (Christ et al., 2011). To verify 
whether increased HR and contractility by chronic infusion of (-)-CGP12177 in the mouse 
was due to stimulation by (-)-CGP12177 of β3-adrenoceptors, we studied β3-adrenoceptor 
knockout and wild-type FVB/n mice receiving 2- or 4-week treatment with (-)-CGP12177 at 
10 mg kg-1 day-1. There were no differences in basal HR and FS values between genotypes 
(Figure 2B). (-)-CGP12177 caused increases in HR to a similar extent in β3-adrenoceptor 
knockout mice compared to wild-type when tested at 2 and 4 weeks drug administration 
(P>0.05, Figure 2B). (-)-CGP12177 caused a slightly greater increase in FS in β3-
14 
 
adrenoceptor knockouts indicating a small cardiodepressant effect of (-)-CGP12177 mediated 
through activation of β3-adrenoceptors.  
Effect of (-)-CGP12177 in mice with chronic TAC. The cardiac effects of (-)-CGP12177 
after chronic TAC were studied in two experiments (Figure 1) with (-)-CGP12177 treatment 
(at 10 mg kg-1 day-1) for 4 weeks (i.e. during weeks 4-8 after TAC, Experiment-1) or 8 weeks 
(i.e. during weeks 4-12 after TAC, Experiment-2). There were no differences between both 
groups at 4 weeks post-TAC prior to commencement of (-)-CGP12177 administration (see 
below). At 4 weeks post-TAC, mice were randomly assigned to receive either (-)-CGP12177 
(10 mg kg-1 day-1) or no treatment for the subsequent 4 or 8 weeks. 
For Experiment-1, TAC for 4 weeks increased LV wall thickness at systole and diastole 
as well as LV mass compared to sham-operated mice, and there were no differences between 
the two TAC groups prior to (-)-CGP12177 (Table 2). At 8 weeks post-TAC (no treatment), 
there was a significant increase in SAP and LVSP, measured proximal to the constriction site, 
compared to sham-operated controls (P<0.05, Table 3). Pulse pressure was increased by 3.6-
fold (Table 3). Other haemodynamic parameters remained unchanged versus that of the 
sham-operated group. Cardiac hypertrophy was evident by a 60-70% increase in LV/body 
mass or heart/body mass ratios (Figure 4). Furthermore, TAC resulted in a 1.3-fold increase 
in LV cardiomyocyte diameter and a 3-fold increase in LV interstitial fibrosis (Figure 5A, B). 
(-)-CGP12177 exacerbated cardiac hypertrophy at 8 weeks post TAC indicated by significant 
further increase in atria/body mass and tendency for increase in LV/body mass and 
heart/body mass, versus untreated TAC group (Figure 4), and increased cardiomyocyte 
diameter by a further 6% versus untreated TAC group (Figure 5A). In addition, in 
Experiment-1 with TAC lasting for 8 weeks, treatment with (-)-CGP12177 compared with 
TAC alone was associated with significant increases in pulse pressure, LVSP, dP/dtmax, 
dP/dtmin and contractility index (Table 3). 
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We examined the extent of changes in cardiac expression of genes related to 
hypertrophy, fibrosis and inflammation.  The untreated TAC group showed multi-fold 
upregulation of fetal genes including -myosin heavy chain, -skeletal actin, atrial and brain 
natriuretic peptides, together with approximately 50% down-regulation of -myosin heavy 
chain, sarcoplasmic reticulum Ca2+-ATPase and 1-adrenoceptor (Figure 6). This group also 
showed upregulation of procollagen-I and connective tissue growth factor (Figure 6). 
Compared with the untreated TAC group, (-)-CGP12177 treatment further increased 
expression of -myosin heavy chain, atrial and brain natriuretic peptides, and upregulated the 
majority of fibrotic-related (procollagen-I, procollagen-III, matrix metalloproteinase 2, 
connective tissue growth factor, transforming growth factor-) and inflammatory genes 
(interleukin-1, monocyte chemotactic protein-1 and NADPH oxidase 2) studied (Figure 6). 
Plasma renin activity was elevated in both groups with TAC but was not affected by 
treatment with (-)-CGP12177 (Figure 6), although kidney/body mass ratio was higher in 
TAC-CGP relative to that of TAC group (Figure 4). 
In the mouse TAC model, development of cardiac decompensation and HF is dependent 
on the duration of TAC (Du et al., 2000; Gao et al., 2005). Therefore, in Experiment-2 we 
studied whether a prolonged treatment of (-)-CGP12177 in mice with TAC would exert 
significant influence on cardiac function and hypertrophy. As for Experiment-1, at 4 weeks 
post TAC, which was prior to the commencement of (-)-CGP12177, the two TAC groups 
were comparable (Figure 7). Compared with mice in Experiment-1 that had TAC for 8 
weeks, prolonged (12 week) TAC in Experiment-2 was associated with more severe cardiac 
hypertrophy and lung wet weight indicating pulmonary congestion (Figure 4).  Under 
isoflurane anaesthesia, echocardiographic tests revealed a progressive increase in LV 
dimensions and decline in FS during 4 to 12 weeks after TAC (Figure 7). (-)-CGP12177 did 
not influence the extent of LV dilatation and decline in FS (Figure 7).  Interestingly, 
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functional examination conducted 3 days after removal of the osmotic minipump, for 
washout of (-)-CGP12177, revealed more severe LV dysfunction. Compared with the TAC 
untreated group, FS, dP/dtmax and dP/dtmin were reduced and Tau was increased, 3 days after 
(-)-CGP12177 was withdrawn from TAC mice that had been treated with the drug for 8 
weeks (Figure 7, Table 4). These data strongly indicate a more severe systolic and diastolic 
dysfunction at the time-point studied, which only became evident once the inotropic effect of 
(-)-CGP12177 was terminated.  
Chronic infusion of (-)-CGP12177 for 8 weeks at 10 mg kg-1 day-1 to mice with TAC 
caused a reduction in β1H-adrenoceptor and β2-adrenoceptor density but not 1L-adrenoceptor 
binding sites compared to TAC only (Table 1, P <0.01).  
The incidence of HF, determined on autopsy findings of mice that died prematurely or at 
the end of the study (following micromanometry), evidenced by presence of chest fluid, 
pulmonary congestion and/or left atrial thrombus (Du et al., 2000), was not significantly 
different between TAC (9/32) and TAC+CGP (14/34) mice from Experiments-1 and -2 
combined (P=0.393, 2 test). These data include 3 premature deaths (as specified in the 
Methods). Based on autopsy findings, all mice had chronic HF.  
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Discussion and Conclusions 
This is the first study that has addressed the cardiac action of β1L-adrenoceptors in vivo 
under physiological and diseased conditions. We have made a few important findings. First, 
activation of β1L-adrenoceptors with (-)-CGP12177 in healthy mice induced a dose-related 
increase in HR and cardiac contractile function. The cardiac action of (-)-CGP12177 is 
largely independent of β3-adrenoceptors. Second, in the setting of chronic pressure overload, 
activation of β1L-adrenoceptors with (-)-CGP12177 tended to exacerbate the degree of cardiac 
hypertrophy and related hypertrophic, fibrotic and inflammatory gene profile. In addition, 
there was a trend for more severe cardiac remodelling in mice with TAC treated with (-)-
CGP12177 for an extended period. Collectively, our findings suggest potentially harmful 
effects of β-blockers that activate β1L-adrenoceptors in cardiac physiology and, importantly, 
under chronic pressure overload. 
Our in vivo studies revealed 1H-blocking as well as 1L-stimulating actions of (-)-
CGP12177 and indicated the importance of experimental conditions. At the lowest dose 
(0.001 mg kg-1) tested, (-)-CGP12177 produced small but insignificant increases in HR in 
animals anaesthetised with ketamine and xylazine, but significant reductions in HR in 
conscious and stressed mice. Both experimental conditions are known to be distinct in terms 
of the sympathetic nervous activity and their affect on -adrenoceptor mediated responses. 
This is reflected by a remarkable difference in mean HR under anesthetised versus conscious 
conditions (343 vs. 713 beats min-1). Our data demonstrated an “opposing action” of (-)-
CGP12177 at 0.001 mg kg-1 on HR as a measure of cardiac 1-adrenoceptor activity, which is 
likely explained by the difference in the degree of 1-adrenoceptor activation by cardiac 
sympathetic drive.  
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β1L-adrenoceptor mediated cardiac stimulatory effects have been well documented using 
isolated cardiac tissues or cardiomyocytes from many species including man (Kaumann and 
Molenaar, 2008). However, there has been an absence of in vivo studies to address 
pathophysiological significance. Therefore in the present study we tested the cardiac effects 
of chronic treatment with (-)-CGP12177 via osmotic minipump. Whilst (-)-CGP12177 blocks 
β1H-adrenoceptors in the nanomolar range (Kaumann and Molenaar, 2008), our in vivo 
observations from healthy animals clearly showed a dose-dependent cardiac stimulating 
action of (-)-CGP12177, which was fully developed at doses of 10-30 mg kg-1 day-1, 
equivalent to 30-95 μM kg-1 range. In comparison with the scale of increment by full 
activation of β1-adrenoceptors with agonists such as isoprenaline as we previously observed 
(Du et al., 2002), the magnitude of cardiac stimulation of (-)-CGP12177 was relatively 
weaker. This is in line with in vitro studies in the mouse right and left atrium (Kaumann et 
al., 1998), human atrial and/or ventricular tissues (Kaumann, 1996; Sarsero et al., 2003) and 
other species (Kaumann and Molenaar, 2008). In an in vitro rat heart preparation treated with 
(-)-propranolol 200 µM, (-)-CGP12177 at 10 µM stimulated protein kinase A to a level of 
about 30% of that to a saturating concentration of (-)-isoprenaline (Kaumann and Lynham, 
1997). Adverse cardiac effects of chronic treatment with isoprenaline at higher doses are well 
known and manifested by enhanced oxidative stress, inflammation, cardiomyocyte apoptosis 
and fibrosis (Chen et al., 2010; Sun et al., 2005; Zhang et al., 2005). We observed that 
chronic administration of (-)-CGP12177 at doses up to 100 mg kg-1 did not result in adverse 
consequences measured by echocardiography, heart weight, histology and gene expression, 
which is likely to be due in part to the fact that a full activation of β1L-adrenoceptors with (-)-
CGP12177 is equivalent to a modest degree of β1H-adrenoceptor stimulation. Another 
interesting feature of β1L-adrenoceptor activation with (-)-CGP12177 is the persistence of the 
cardiac stimulatory effect. This was indicated by haemodynamic responses to (-)-CGP12177 
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given as a bolus, or throughout the 4-week period studied, suggesting the lack of 
desensitization of β1L-adrenoceptor under such conditions.  
We detected down-regulation of 1H (+2), but not 1L-adrenoceptor binding site 
numbers following 4-week infusion of (-)-CGP12177 at doses over 10 mg kg-1 day-1. Similar 
changes were observed in hypertrophic hearts without and with (-)-CGP12177 treatment. In 
these experiments, (-)-[3H]CGP12177 binds to both 1H and 2-adrenoceptors. Due to 
insufficient quantities of tissues we did not delineate between 1H and 2-adrenoceptors. Our 
assay for 1H+2–adrenoceptor binding would largely reflect changes in 1H-adrenoceptors 
that account for ~80% of -adrenoceptors in the heart. In LVs from mice with TAC or 
TAC+CGP at 10 mg kg-1 day-1, both groups showed a reduction in 1-adrenoceptor mRNA 
compared to control.  It has been well documented that in the setting of heart disease and 
failure, 1- but not 2-adrenoceptor signalling is desensitized, partially through loss of 
receptors from cellular membranes (i.e. down-regulation), and through reduced gene 
transcription (Bristow et al., 1986; Bristow, 2000; Lohse et al., 2003). Such changes are due, 
for the most part, to sustained agonist stimulation. While 1H- and 1L-adrenoceptor binding 
sites are separate, they are on the same receptor. Therefore it is feasible, although not proven, 
that chronic agonist activation of 1L-adrenoceptors also reduces 1H-adrenoceptor binding 
sites, due to a loss of 1-adrenoceptors.  
Previous studies on the mouse TAC model, including ours (Gao et al., 2005; Sheridan et 
al., 2000), have documented the dynamic evolution from compensatory hypertrophy to 
functional decompensation and ultimately HF. We carefully examined the consequence of 
chronic activation of β1L-adrenoceptors with (-)-CGP12177 in mice with TAC. 
Cardiostimulant effects of (-)-CGP12177 were evident by either non-invasive 
echocardiography or invasive micromanometry conducted during the treatment period up to 
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12 weeks after TAC. Our results indicate that mice treated with (-)-CGP12177 during weeks 
4-8 after TAC underwent more severe ventricular remodelling (increase in atrial weight, 
cardiomyocyte size and hypertrophic gene pattern as well as expression of fibrogenic or 
inflammatory genes). These effects occurred despite such treatment resulting in a moderate 
increase in ventricular contractile function. This is the first in vivo documentation under 
conditions of pressure overload hypertrophy that β1L-adrenoceptor activation adversely 
impacts on cardiac remodelling at the organ, cellular and molecular levels.  
Higher levels of SAP, pulse pressure and LVSP were observed at week-8 after TAC in 
the presence of (-)-CGP12177, compared to the corresponding untreated TAC group. While 
these parameters are commonly used for assessment of degree of pressure overload, such a 
difference is unlikely to be explained by a difference in the degree of pressure overload 
because TAC surgery and animal allocation to vehicle or (-)-CGP121777 treatment at week-4 
was carried out without information of ultimate grouping. Furthermore, functional assessment 
at 4 weeks did not reveal any differences between TAC and TAC+CGP groups prior to 
commencement of (-)-CGP12177 treatment. Such differences in the presence of (-)-
CGP12177 are most likely due to an enhanced contractility as a consequence of β1L-
adrenoceptor stimulation, which further augmented SAP when the LV pumps blood against a 
fixed resistance (aortic constriction). In Experiment-2 when haemodynamic measures were 
performed after washout of (-)-CGP12177, there was a trend for lower levels of SAP and 
LVSP in comparison to that of the untreated TAC group. This is attributable to development 
of ventricular contractile dysfunction reflected by a significant reduction in dP/dtmax and FS 
in the treated group.   
Chronic use of β1-adrenoceptor agonists such as isoprenaline in rodents is well known to 
induce cardiac pathology and dysfunction (Chen et al., 2010; Sun et al., 2005; Zhang et al., 
2005). Whereas chronic activation of β1L-adrenoceptors with (-)-CGP12177 resulted in 
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evident functional enhancement, this action was not associated with change in gene 
expression in the myocardium of normal mice without TAC. In the presence of TAC, 
however, chronic β1L-adrenoceptor stimulation by (-)-CGP12177 exacerbated the extent of 
gene expression known to lead to adverse remodelling and dysfunction in hearts with 
pressure-overload hypertrophy.  
End-stage human HF is associated with a loss of both 1H-adrenoceptor (+2-
adrenoceptor) and 1L-adrenoceptor binding sites (Sarsero et al., 2003) and desensitization of 
inotropic responses mediated through activation of 1H-adrenoceptors (Bristow et al., 1986; 
Molenaar et al., 2007) and 1L-adrenoceptors (Sarsero et al., 2003) in human heart tissues. 
Human HF is characterized by increased sympathetic nervous activity, noradrenaline 
spillover and activation of β1H-adrenoceptors (Bristow, 2000; Bristow et al., 2003; Cohn et 
al., 1984; Esler et al., 1997). Chronic activation of β1-adrenoceptors causes progression of 
HF resulting in adverse remodelling, haemodynamic dysfunction, morbidity and mortality. 
Further insight into the pathological role of β1-adrenoceptors was obtained from transgenic 
mice with 15-fold overexpression of cardiac β1-adrenoceptors, which exhibited initial 
enhancement of heart function at a young age, followed by progressive deterioration that 
included hypertrophy and HF, sharing similar features with human HF (Engelhardt et al., 
1999). Despite progress in the management of human HF with the implementation of 
currently used β-blockers that reverse adverse cardiac remodelling and improve cardiac 
function, the long-term prognosis of patients with HF unfortunately is still extremely poor. 
The present study provides appealing evidence for a role of β1L-adrenoceptor activation in 
promoting adverse cardiac remodelling and functional dysfunction.  
While the pharmacological significance of 1L-adrenoceptor has been shown ex vivo, its 
role in vivo under diseased conditions remains speculative. In this study on mice with chronic 
pressure overload, activation of 1L-adrenoceptors by the exogenous agonist (-)-CGP12177 
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led to adverse consequences. Thus, in the setting of heart disease, activation of 1L-
adrenoceptors by some -blockers (Kaumann and Molenaar, 2008) is likely and their use 
should be avoided. However, future studies are required to test this possibility. 
Conclusion.  Using (-)-CGP12177 as β1L-adrenoceptor agonist, we have documented in 
vivo a functional stimulatory action mediated by β1L-adrenoceptors in healthy and diseased 
mouse heart, which was maintained throughout the study period of 4 or 8 weeks. Whilst 
activation of β1L-adrenoceptors using (-)-CGP12177 in healthy animals did not result in 
adverse consequences, such an intervention exacerbates cardiac remodelling in the setting of 
chronic pressure overload and functional decompensation. Our results suggest that 
cardiostimulation through β1L-adrenoceptors by a β-blocker could potentially worsen cardiac 
disease, thereby decreasing the beneficial effects of blockade of β1H-adrenoceptors.   
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Table 1.  Maximal density of 1H + 2-adrenoceptor and 1L-adrenoceptor binding sites 
determined with (-)-[3H]-CGP12177 and influence of (-)-CGP12177 treatment in healthy and 
hypertrophic (TAC) hearts.  
 
(-)-CGP12177 dose rate n β1H + β2 
 β1L 
 
 
   
4 weeks 
No treatment 
 
8 
 
7.58 ± 0.44 
 
48.4 ± 5.4 
1 mg kg-1 day-1 3 5.76 ± 0.18 34.0 ± 7.3 
10 mg kg-1 day-1 3    5.53 ± 0.48*  43.5 ± 0.6 
30 mg kg-1 day-1 4   5.55 ± 0.39* 47.5 ± 2.9 
    
Experiment-2 
TAC 
 
6 
 
7.30 ± 0.32 
 
50.7 ± 7.5 
TAC+10 mg kg-1 day-1 6    6.08 ± 0.19#  47.4 ± 2.9 
 
TAC: transverse aorta constriction. Values expressed as fmol mg-1 protein. *P<0.05 
compared to No treatment (one-way ANOVA for multiple groups (No treatment, 1, 10, 30 
mg kg-1 day-1)); #P<0.01 vs. TAC (Student’s unpaired t test) 
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Table 2. Experiment-1: Cardiac functional parameters by echocardiography at 4 weeks post 
sham or transverse aorta constriction (TAC) surgery and immediately prior to 
commencement of (-)-CGP12177 (CGP) treatment. 
 Sham  
(n=8) 
TAC 
(n=20) 
 
TAC+CGP 
(n=21) 
    
Heart rate (beats min-1) 470±13 487±11 475±4 
LV diastolic dimension (mm) 4.21±0.07 4.16±0.07 4.34±0.08 
LV systolic dimension (mm) 2.92±0.10 2.96±0.06 2.99±0.07 
Diastolic wall thickness (mm) 0.69±0.04 0.98±0.03* 0.98±0.04* 
Systolic wall thickness (mm) 1.08±0.05 1.41±0.03* 1.45±0.04* 
Fractional Shortening (%) 31±2 29±1 31±1 
LV mass (mg) 107±9 165±6* 178±8* 
 
LV: left ventricle; *P<0.05 vs. Sham (one-way ANOVA) 
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Table 3. Experiment-1: Cardiac haemodynamic parameters by micromanometry in untreated 
mice with transverse aorta constriction (TAC) for 8 weeks and TAC mice receiving 
(-)-CGP12177 at 10 mg kg-1 day-1 during weeks 4 to 8 (TAC+CGP). 
 Sham  
(n=8) 
TAC 
(n=16) 
 
TAC+CGP 
(n=18) 
    
Heart rate (beats min-1) 435±21 462±14 486±11 
Systolic aortic pressure (mmHg) 94±4 172±7* 200±4*# 
Diastolic aortic pressure (mmHg) 65±3 66±2 71±2 
Pulse pressure (mmHg) 29±1 106±6* 129±4*# 
LV systolic pressure (mmHg) 98±3 175±7* 204±3*# 
LV end-diastolic pressure (mmHg) 6±1 8±1 9±1 
dP/dtmax (mmHg s-1) 8465±1499 9039 ±536 11005±359*# 
dP/dtmin (mmHg s-1) -7718±928 -8990±469 -11260±500*# 
Contractility index (s-1) 160±18 184±7 201±7# 
Tau (ms) 13±1 12±1 10±1 
 
Aortic pressures were measured proximal to the constriction site. dP/dtmax and dP/dtmin: 
maximal rates of rise and fall of LV pressure, respectively.  
*P<0.05 vs. Sham, #P<0.05 vs. TAC (one-way ANOVA) 
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Table 4. Experiment-2: Cardiac haemodynamic parameters by micromanometry for untreated 
mice with transverse aorta constriction (TAC) for 12 weeks, and 3 days after (-)-CGP12177 
was withdrawn from TAC mice treated with the drug during weeks 8 to 12 (TAC±CGP) 
 
dP/dtmax and dP/dtmin: maximal rates of rise and fall of LV pressure, respectively.  
*P<0.05 vs. TAC control group (Student’s unpaired t test) 
 TAC 
(n=10) 
 
TAC±CGP 
(n=11) 
   
Heart rate (beats min-1) 517 ± 19 475 ± 16 
Systolic aortic pressure (mmHg) 193 ± 6 180 ± 8 
Diastolic aortic pressure (mmHg) 71 ± 4 64 ± 3 
Pulse pressure (mmHg) 122 ± 5 117 ± 5 
LV systolic pressure (mmHg) 202 ± 6 179 ± 10 
LV end-diastolic pressure (mmHg) 6 ± 1 7 ± 1 
dP/dtmax (mmHg s-1) 11106 ± 635 9056 ± 627* 
dP/dtmin (mmHg s-1) -11663 ±735 -8251 ± 540* 
Contractility index (s-1) 203 ± 8 192 ± 8 
Tau (ms) 10 ± 1 14 ± 1* 
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FIGURE LEGENDS 
 
Figure 1. Experimental protocols on mice with transverse aorta constriction (TAC) for a 
period of either 8 weeks (Exp-1, Experiment-1) or 12 weeks (Exp-2, Experiment-2). Echo, 
echocardiography; CGP, (-)-CGP12177 delivered by osmotic minipump (* indicates 
minipump implantation surgery). 
 
Figure 2.  Cardiac effect of chronic infusion (2 and 4 weeks) of (-)-CGP12177 (CGP) in 
C57Bl/6 mice (A, n=4-8 per group), and in β3-adrenoceptor knockout (KO) or wild-type 
control FVB/n mice (B, n=5-6 per group). A, There was a statistically significant effect of 
drug dose on both heart rate and fractional shortening (P<0.05, two-way ANOVA). Removal 
of the osmotic minipump containing CGP abolished the increase in heart rate and fractional 
shortening (*P<0.05 vs. 4-week, two-way ANOVA); B, CGP had a stimulatory effect on 
heart rate and fractional shortening in both control and KO mice. #P<0.05 vs. control with 
same genotype; †P<0.05 vs. WT with same treatment (one-way ANOVA). 
 
Figure 3. Changes in cardiac functional parameters induced by acute intravenous infusion 
with (-)-CGP12177 (CGP) in C57Bl/6 mice. A, heart rate at baseline and 5, 30 and 70 min 
post bolus injection of CGP (at 0.001 mg kg-1) in conscious and restrained mice. *P<0.05 vs. 
baseline; #P<0.05 vs. 5 and 30 min timepoints (one-way repeated measures ANOVA). B, 
CGP dose-haemodynamic response relations. Each animal received a single dose and n=5-6 
mice per group with the baseline data combined from all animals. The drug effect was 
statistically significant for all parameters (P<0.05, one-way ANOVA). If error bars are not 
visible they are contained within the symbol. 
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Figure 4. Organ weights normalized by body mass (BM) in mice subjected to sham surgery 
or transverse aorta constriction (TAC) for either 8 (Experiment-1) or 12 weeks (Experiment-
2) with and without treatment of (-)-CGP12177 (CGP) at 10 mg kg-1 day-1. Sham data from 8 
and 12 weeks were combined. There was a significant increase in tissue/BM ratio between 8 
and 12 weeks post TAC for all tissues (P<0.05, two-way ANOVA). P values shown indicate 
comparison between TAC and TAC+CGP groups (two-way ANOVA). TAC-CGP mice had 
increased Kidney/BM and atrial/BM ratios, and there was a trend for an increase in LV/BM 
and Heart/BM ratios. n=14-21. *P<0.05 vs. sham-operated control. 
 
Figure 5. Histological changes in the left ventricle taken from mice subjected to sham 
surgery or transverse aorta constriction (TAC) and TAC with (-)-CGP12177 treatment 
(TAC+CGP) from Experiment-1. A, chronic TAC caused an increase in cardiomyocyte (CM) 
diameter, which was further increased by (-)-CGP12177 (40 magnification, n=6-10). B, 
interstitial fibrosis measured by picrosirus red staining for collagen with results expressed as 
percentage of view field (10x magnification, n=6-10). There was a trend for more severe 
fibrosis in TAC+CGP group (P=0.09) compared to the untreated TAC group. *P<0.05 vs. 
sham-operated control; #P<0.05 vs. TAC (one-way ANOVA).  
 
Figure 6. Changes in gene expression of the left ventricular myocardium and plasma rennin 
from mice subjected to sham surgery, transverse aorta constriction (TAC) or TAC together 
with (-)-CGP12177 treatment (TAC+CGP) from Experiment-1. By quantitative real-time 
PCR, expression of the following selected genes were determined: atrial or brain natriuretic 
peptide (ANP, BNP), - or -myosin heavy chain (-, -MHC), -skeletal actin (-skA), -
smooth muscle actin (-SMA), β1-adrenoceptor (β1-AR), sarcoplasmic reticulum Ca2+-
ATPase (SERCA2a), transforming growth factor- (TGF-), connective tissue growth factor 
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(CTGF), procollagen-I, procollagen-III, matrix metalloproteinase 2 (MMP-2), interleukin-1 
(IL-1), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), and NADPH oxidase 
2 (Nox-2). Gene expression levels were normalized by that of glyceraldehyde-3-phosphate 
dehydrogenase as house-keeping gene and expressed as fold change of sham group value. 
n=4-8. *P<0.05 vs. sham-operated control; #P<0.05 vs. TAC (one-way ANOVA).  
 
Figure 7.  Changes in echocardiographic measures of LV function and dimensions in mice 
with transverse aorta constriction (TAC) for 12 weeks without and with treatment of (-)-CGP 
12177 during 4 to 12 weeks (TAC+CGP) from Experiment-2.  The 4-week echocardiography 
was just prior to minipump implantation in the (-)-CGP12177 treated group, and shows that 
both TAC groups (TAC vs. TAC + CGP) had similar parameters at this pre-treatment 
timepoint. Across the 12 weeks both TAC groups were similar, with only an effect of time 
evident (horizontal lines with P value on top of graphs, from two-way repeated measures 
ANOVA). Immediately after the 12 week echocardiography, minipumps were removed from 
the (-)-CGP12177 treated animals, and an additional echocardiography was performed 3 days 
later to allow for drug washout (W). n=10-12 per group. #P<0.05 vs. TAC at same timepoint 
(Student’s unpaired t test).  
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